NASDAQ:LTRN Lantern Pharma (LTRN) Stock Price, News & Analysis $3.31 +0.19 (+6.09%) (As of 11/1/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About Lantern Pharma Stock (NASDAQ:LTRN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Lantern Pharma alerts:Sign Up Key Stats Today's Range$3.05▼$3.3150-Day Range$3.13▼$4.6452-Week Range$2.53▼$11.99Volume20,492 shsAverage Volume136,467 shsMarket Capitalization$35.65 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingHold Company OverviewLantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1 clinical trial for the treatment of solid tumor, such as pancreatic, breast, bladder, and lung cancers, and glioblastoma and other central nervous system cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma. The company develops STAR-001, which is in preclinical development for the treatment of glioblastoma, brain metastases, atypical teratoid rhabdoid tumors, and pediatric rare disease designation. In addition, it provides ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Further, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. Lantern Pharma Inc. has a strategic AI-driven collaboration with Oregon Therapeutics to optimize the development of its first-in-class protein disulfide isomerase inhibitor drug candidate XCE853 in novel and targeted cancer indications. The company was incorporated in 2013 and is headquartered in Dallas, Texas.Read More… Sell NVDA Now? (Ad)Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's what that means for your money. Billionaire Wall Street investors are quietly offloading millions of shares. What do they know that you don't? It's arguably the most popular stock in the world. Now, one 50-year Wall Street legend says its day in the sun could finally be coming to an end. Last year, he warned of two stocks that went on to crash 60%.Now he's just issued a warning for the most popular stock in the world: Nvidia (NVDA). Lantern Pharma Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks18th Percentile Overall ScoreLTRN MarketRank™: Lantern Pharma scored higher than 18% of companies evaluated by MarketBeat, and ranked 906th out of 975 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Lantern Pharma.Read more about Lantern Pharma's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Lantern Pharma are expected to grow in the coming year, from ($2.12) to ($2.02) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Lantern Pharma is -1.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Lantern Pharma is -1.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLantern Pharma has a P/B Ratio of 0.86. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Lantern Pharma's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.21% of the float of Lantern Pharma has been sold short.Short Interest Ratio / Days to CoverLantern Pharma has a short interest ratio ("days to cover") of 3.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Lantern Pharma has recently decreased by 6.89%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldLantern Pharma does not currently pay a dividend.Dividend GrowthLantern Pharma does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted2.21% of the float of Lantern Pharma has been sold short.Short Interest Ratio / Days to CoverLantern Pharma has a short interest ratio ("days to cover") of 3.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Lantern Pharma has recently decreased by 6.89%, indicating that investor sentiment is improving significantly. News and Social Media0.7 / 5News SentimentN/A News SentimentLantern Pharma has a news sentiment score of -0.79. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.41 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Lantern Pharma this week, compared to 1 article on an average week.Search InterestOnly 2 people have searched for LTRN on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Lantern Pharma to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Lantern Pharma insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.31% of the stock of Lantern Pharma is held by insiders.Percentage Held by InstitutionsOnly 28.62% of the stock of Lantern Pharma is held by institutions.Read more about Lantern Pharma's insider trading history. Receive LTRN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lantern Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address LTRN Stock News HeadlinesLantern Pharma to Report Third Quarter 2024 Operating & Financial Results on November 7th, 2024 at 4:30 p.m. ETOctober 31 at 9:33 PM | businesswire.comLantern Pharma to Host & Participate in Two Public Webinars During OctoberOctober 21, 2024 | finance.yahoo.comSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's what that means for your money. Billionaire Wall Street investors are quietly offloading millions of shares. What do they know that you don't? It's arguably the most popular stock in the world. Now, one 50-year Wall Street legend says its day in the sun could finally be coming to an end. Last year, he warned of two stocks that went on to crash 60%.November 2, 2024 | Chaikin Analytics (Ad)Lantern Pharma’s Investigational Drug-Candidate, LP-184, Receives Fast-Track Designation in Glioblastoma from the FDAOctober 15, 2024 | finance.yahoo.comLantern Pharma Inc (LTRN) Q2 2024 Earnings Call Highlights: Promising Clinical Trials and ...October 9, 2024 | finance.yahoo.comLantern Pharma (NASDAQ:LTRN) Stock, Insider Trading ActivityOctober 9, 2024 | benzinga.comLantern Pharma Announces Three U.S. FDA Rare Pediatric Disease Designations Granted to LP-184 in Multiple Ultra Rare Children’s CancersSeptember 24, 2024 | finance.yahoo.comLantern Pharma Gets Three FDA Rare-Pediatric Designations for LP-184September 23, 2024 | marketwatch.comSee More Headlines LTRN Stock Analysis - Frequently Asked Questions How have LTRN shares performed this year? Lantern Pharma's stock was trading at $4.28 at the beginning of 2024. Since then, LTRN stock has decreased by 24.1% and is now trading at $3.25. View the best growth stocks for 2024 here. How were Lantern Pharma's earnings last quarter? Lantern Pharma Inc. (NASDAQ:LTRN) announced its quarterly earnings data on Thursday, August, 8th. The company reported ($0.46) EPS for the quarter, topping analysts' consensus estimates of ($0.55) by $0.09. When did Lantern Pharma IPO? Lantern Pharma (LTRN) raised $26 million in an IPO on Thursday, June 11th 2020. The company issued 1,600,000 shares at $15.00-$17.00 per share. ThinkEquity (a division of Fordham Financial Management) served as the underwriter for the IPO and Dougherty & Company and Paulson Investment Company were co-managers. How do I buy shares of Lantern Pharma? Shares of LTRN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Lantern Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Lantern Pharma investors own include NVIDIA (NVDA), Tesla (TSLA), Palantir Technologies (PLTR), Advanced Micro Devices (AMD), Intel (INTC), Meta Platforms (META) and NIO (NIO). Company Calendar Last Earnings8/08/2024Today11/02/2024Next Earnings (Confirmed)11/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:LTRN CUSIPN/A CIK1763950 Webwww.lanternpharma.com Phone972-277-1136FaxN/AEmployees20Year Founded2013Profitability EPS (Most Recent Fiscal Year)($1.65) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-15,960,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-46.40% Return on Assets-42.58% Debt Debt-to-Equity RatioN/A Current Ratio7.67 Quick Ratio7.67 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.76 per share Price / Book0.86Miscellaneous Outstanding Shares10,770,000Free Float9,978,000Market Cap$35.00 million OptionableOptionable Beta1.55 Social Links 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report This page (NASDAQ:LTRN) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredNvidia warning urgentI thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredNothing can stop this gold rallyAfter what's felt like nearly a decade of disappointing gains, gold is stronger than ever and continues to hit...Stansberry Research | SponsoredWall St. Legend: Millions of Americans About to Fall Out of the 1%Wall Street insider reveals the financial tidal wave about to knock millions of Americans out of the One Perce...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lantern Pharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lantern Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.